CareRx (CRRX) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
23 Mar, 2026Market opportunity and demand trends
1 in 5 Canadians are aged 65 or older, with seniors consuming about 40% of prescription drugs and 25% of OTC drugs.
Over 500,000 congregate care beds exist in Canada, projected to double in 15 years.
Senior population expected to grow by 1.5 million to 9.3 million in five years, driving care spending from $29.9B in 2021 to $58.5B by 2031.
Ontario government plans to build 58,000 new or upgraded LTC beds by 2028.
Business model and service offering
Specializes in pharmacy services for seniors housing, focusing on complex medication needs and same-day delivery.
Operates a purpose-built model distinct from retail pharmacy, offering tailored clinical and operational support for LTC homes.
Delivers integrated clinical, operational, and distribution solutions, promoting long-term partnerships.
Contracts are typically over five years, with direct government and insurance payments, ensuring stable recurring revenue.
Growth strategy and execution
Growth driven by organic bed wins, expansion with existing partners, new home construction, and M&A.
Track record of accretive acquisitions since 2020 in a fragmented market.
Focus on expanding product and service scope and leveraging scale for superior offerings.
Latest events from CareRx
- Strong revenue, margin, and net income growth, plus new dividends and share buybacks.CRRX
Q4 20255 Mar 2026 - Q2 2024 saw $92M revenue, $7.5M EBITDA, margin gains, and a strong outlook for growth.CRRX
Q2 20242 Feb 2026 - Fifth straight quarter of EBITDA growth, margin gains, and new beds drive 2025 expansion.CRRX
Q3 202415 Jan 2026 - Revenue and EBITDA grew, debt fell by CAD 21.8M, and operational efficiency improved.CRRX
Q4 202416 Dec 2025 - Stable revenue, margin gains, and new growth initiatives drive positive Q1 results.CRRX
Q1 202525 Nov 2025 - Q2 2025 saw $91.4M revenue, $8.0M EBITDA, $0.6M net income, and strong growth prospects.CRRX
Q2 202516 Nov 2025 - Q3 2025 saw strong revenue, margin expansion, and new dividends and share buybacks.CRRX
Q3 202513 Nov 2025